Global Influenza (Flu) Antiviral Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Published: November 2022

No. of Pages: 115

Price:

Single User License: US $ 5600

Corporate User License: US $ 11200

Report Description
Table of Contents

Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Influenza (Flu) Antiviral Drugs companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Influenza (Flu) Antiviral Drugs market. Further, it explains the major drivers and regional dynamics of the global Influenza (Flu) Antiviral Drugs market and current trends within the industry.

Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
- Pfizer
- Roche
- Sanofi
- Johnson & Johnson
- Merck & Co. (MSD)
- Novartis
- AbbVie
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Teva
- Bayer
- Novo Nordisk
- Allergan
- Takeda
- Boehringer Ingelheim

Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Influenza (Flu) Antiviral Drugs Segment by Type
- Penetration and Dehulling Inhibitors
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protein Inhibitors
- Neuraminidase Inhibitors
- Broad-spectrum Antiviral Drugs
Influenza (Flu) Antiviral Drugs Segment by Application
- Hospital
- Clinic
- Household
- Others

Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
- North America
- - United States
- - Canada
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Nordic Countries
- - Rest of Europe
- Asia-Pacific
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Australia
- - Rest of Asia
- Latin America
- - Mexico
- - Brazil
- - Rest of Latin America
- Middle East & Africa
- - Turkey
- - Saudi Arabia
- - UAE
- - Rest of MEA

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Influenza (Flu) Antiviral Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:
This report presents an overview of global market for Influenza (Flu) Antiviral Drugs market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Influenza (Flu) Antiviral Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Influenza (Flu) Antiviral Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenza (Flu) Antiviral Drugs revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Influenza (Flu) Antiviral Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Influenza (Flu) Antiviral Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences and GlaxoSmithKline (GSK), etc.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Penetration and Dehulling Inhibitors
1.2.3 DNA Polymerase Inhibitors
1.2.4 Reverse Transcriptase Inhibitors
1.2.5 Protein Inhibitors
1.2.6 Neuraminidase Inhibitors
1.2.7 Broad-spectrum Antiviral Drugs
1.3 Market by Application
1.3.1 Global Influenza (Flu) Antiviral Drugs Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Influenza (Flu) Antiviral Drugs Market Size (2017-2028)
2.2 Influenza (Flu) Antiviral Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Influenza (Flu) Antiviral Drugs Market Size by Region (2017-2022)
2.4 Global Influenza (Flu) Antiviral Drugs Market Size Forecast by Region (2023-2028)
2.5 Global Top Influenza (Flu) Antiviral Drugs Countries Ranking by Market Size
3 Influenza (Flu) Antiviral Drugs Competitive by Company
3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Players
3.1.1 Global Influenza (Flu) Antiviral Drugs Revenue by Players (2017-2022)
3.1.2 Global Influenza (Flu) Antiviral Drugs Market Share by Players (2017-2022)
3.2 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
3.4 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2021
3.5 Global Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Influenza (Flu) Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Influenza (Flu) Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza (Flu) Antiviral Drugs Historic Revenue by Type (2017-2022)
4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Revenue by Type (2023-2028)
5 Global Influenza (Flu) Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Application (2017-2022)
5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022)
6.2 North America Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2028)
6.3 North America Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2028)
6.4 North America Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022)
7.2 Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2028)
7.3 Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2028)
7.4 Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022)
8.2 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022)
9.2 Latin America Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2028)
9.3 Latin America Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2028)
9.4 Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022)
10.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Influenza (Flu) Antiviral Drugs Products and Services
11.1.4 Pfizer Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.1.5 Pfizer Influenza (Flu) Antiviral Drugs SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Influenza (Flu) Antiviral Drugs Products and Services
11.2.4 Roche Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.2.5 Roche Influenza (Flu) Antiviral Drugs SWOT Analysis
11.2.6 Roche Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Influenza (Flu) Antiviral Drugs Products and Services
11.3.4 Sanofi Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.3.5 Sanofi Influenza (Flu) Antiviral Drugs SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Products and Services
11.4.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.4.5 Johnson & Johnson Influenza (Flu) Antiviral Drugs SWOT Analysis
11.4.6 Johnson & Johnson Recent Developments
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Details
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Products and Services
11.5.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.5.5 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs SWOT Analysis
11.5.6 Merck & Co. (MSD) Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Influenza (Flu) Antiviral Drugs Products and Services
11.6.4 Novartis Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.6.5 Novartis Influenza (Flu) Antiviral Drugs SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Influenza (Flu) Antiviral Drugs Products and Services
11.7.4 AbbVie Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.7.5 AbbVie Influenza (Flu) Antiviral Drugs SWOT Analysis
11.7.6 AbbVie Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Products and Services
11.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.8.5 Gilead Sciences Influenza (Flu) Antiviral Drugs SWOT Analysis
11.8.6 Gilead Sciences Recent Developments
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Details
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Products and Services
11.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.9.5 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs SWOT Analysis
11.9.6 GlaxoSmithKline (GSK) Recent Developments
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Influenza (Flu) Antiviral Drugs Products and Services
11.10.4 Amgen Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.10.5 Amgen Influenza (Flu) Antiviral Drugs SWOT Analysis
11.10.6 Amgen Recent Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Company Details
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Products and Services
11.11.4 AstraZeneca Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.11.5 AstraZeneca Recent Developments
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Details
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Products and Services
11.12.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.12.5 Bristol-Myers Squibb Recent Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Products and Services
11.13.4 Eli Lilly Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.13.5 Eli Lilly Recent Developments
11.14 Teva
11.14.1 Teva Company Details
11.14.2 Teva Business Overview
11.14.3 Teva Influenza (Flu) Antiviral Drugs Products and Services
11.14.4 Teva Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.14.5 Teva Recent Developments
11.15 Bayer
11.15.1 Bayer Company Details
11.15.2 Bayer Business Overview
11.15.3 Bayer Influenza (Flu) Antiviral Drugs Products and Services
11.15.4 Bayer Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.15.5 Bayer Recent Developments
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Details
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Products and Services
11.16.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.16.5 Novo Nordisk Recent Developments
11.17 Allergan
11.17.1 Allergan Company Details
11.17.2 Allergan Business Overview
11.17.3 Allergan Influenza (Flu) Antiviral Drugs Products and Services
11.17.4 Allergan Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.17.5 Allergan Recent Developments
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Influenza (Flu) Antiviral Drugs Products and Services
11.18.4 Takeda Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.18.5 Takeda Recent Developments
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Products and Services
11.19.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022)
11.19.5 Boehringer Ingelheim Recent Developments
12 Influenza (Flu) Antiviral Drugs Market Dynamics
12.1 Influenza (Flu) Antiviral Drugs Market Trends
12.2 Influenza (Flu) Antiviral Drugs Market Drivers
12.3 Influenza (Flu) Antiviral Drugs Market Challenges
12.4 Influenza (Flu) Antiviral Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Tables
Table 1. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Penetration and Dehulling Inhibitors
Table 3. Key Players of DNA Polymerase Inhibitors
Table 4. Key Players of Reverse Transcriptase Inhibitors
Table 5. Key Players of Protein Inhibitors
Table 6. Key Players of Neuraminidase Inhibitors
Table 7. Key Players of Broad-spectrum Antiviral Drugs
Table 8. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 9. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 10. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2017-2022)
Table 12. Global Influenza (Flu) Antiviral Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 13. Global Influenza (Flu) Antiviral Drugs Market Share by Players (2017-2022)
Table 14. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2021)
Table 15. Ranking of Global Top Influenza (Flu) Antiviral Drugs Companies by Revenue (US$ Million) in 2021
Table 16. Global 5 Largest Players Market Share by Influenza (Flu) Antiviral Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 17. Key Players Headquarters and Area Served
Table 18. Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
Table 19. Date of Key Manufacturers Enter into Influenza (Flu) Antiviral Drugs Market
Table 20. Mergers & Acquisitions, Expansion Plans
Table 21. Global Influenza (Flu) Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 22. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2017-2022)
Table 23. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 24. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2023-2028)
Table 25. Global Influenza (Flu) Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 26. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2017-2022)
Table 27. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 28. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2023-2028)
Table 29. North America Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 30. North America Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 31. North America Influenza (Flu) Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 32. North America Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 33. North America Influenza (Flu) Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 34. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 35. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 36. Europe Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 37. Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 38. Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 39. Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 40. Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 41. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 42. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 44. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 50. Latin America Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 51. Latin America Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 52. Latin America Influenza (Flu) Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 53. Latin America Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 54. Latin America Influenza (Flu) Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 55. Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 56. Latin America Influenza (Flu) Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 58. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer Influenza (Flu) Antiviral Drugs Product and Services
Table 67. Pfizer Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 68. Pfizer Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 69. Pfizer Recent Developments
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Influenza (Flu) Antiviral Drugs Product and Services
Table 73. Roche Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 74. Roche Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 75. Roche Recent Developments
Table 76. Sanofi Company Details
Table 77. Sanofi Business Overview
Table 78. Sanofi Influenza (Flu) Antiviral Drugs Product and Services
Table 79. Sanofi Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 80. Sanofi Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 81. Sanofi Recent Developments
Table 82. Johnson & Johnson Company Details
Table 83. Johnson & Johnson Business Overview
Table 84. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product and Services
Table 85. Johnson & Johnson Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 86. Johnson & Johnson Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 87. Johnson & Johnson Recent Developments
Table 88. Merck & Co. (MSD) Company Details
Table 89. Merck & Co. (MSD) Business Overview
Table 90. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product and Services
Table 91. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 92. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 93. Merck & Co. (MSD) Recent Developments
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Influenza (Flu) Antiviral Drugs Product and Services
Table 97. Novartis Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 98. Novartis Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 99. Novartis Recent Developments
Table 100. AbbVie Company Details
Table 101. AbbVie Business Overview
Table 102. AbbVie Influenza (Flu) Antiviral Drugs Product and Services
Table 103. AbbVie Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 104. AbbVie Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 105. AbbVie Recent Developments
Table 106. Gilead Sciences Company Details
Table 107. Gilead Sciences Business Overview
Table 108. Gilead Sciences Influenza (Flu) Antiviral Drugs Product and Services
Table 109. Gilead Sciences Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 110. Gilead Sciences Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 111. Gilead Sciences Recent Developments
Table 112. GlaxoSmithKline (GSK) Company Details
Table 113. GlaxoSmithKline (GSK) Business Overview
Table 114. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product and Services
Table 115. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 116. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 117. GlaxoSmithKline (GSK) Recent Developments
Table 118. Amgen Company Details
Table 119. Amgen Business Overview
Table 120. Amgen Influenza (Flu) Antiviral Drugs Product and Services
Table 121. Amgen Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 122. Amgen Influenza (Flu) Antiviral Drugs SWOT Analysis
Table 123. Amgen Recent Developments
Table 124. AstraZeneca Company Details
Table 125. AstraZeneca Business Overview
Table 126. AstraZeneca Influenza (Flu) Antiviral Drugs Product and Services
Table 127. AstraZeneca Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 128. AstraZeneca Recent Developments
Table 129. Bristol-Myers Squibb Company Details
Table 130. Bristol-Myers Squibb Business Overview
Table 131. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product and Services
Table 132. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 133. Bristol-Myers Squibb Recent Developments
Table 134. Eli Lilly Company Details
Table 135. Eli Lilly Business Overview
Table 136. Eli Lilly Influenza (Flu) Antiviral Drugs Product and Services
Table 137. Eli Lilly Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 138. Eli Lilly Recent Developments
Table 139. Teva Company Details
Table 140. Teva Business Overview
Table 141. Teva Influenza (Flu) Antiviral Drugs Product and Services
Table 142. Teva Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 143. Teva Recent Developments
Table 144. Bayer Company Details
Table 145. Bayer Business Overview
Table 146. Bayer Influenza (Flu) Antiviral Drugs Product and Services
Table 147. Bayer Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 148. Bayer Recent Developments
Table 149. Novo Nordisk Company Details
Table 150. Novo Nordisk Business Overview
Table 151. Novo Nordisk Influenza (Flu) Antiviral Drugs Product and Services
Table 152. Novo Nordisk Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 153. Novo Nordisk Recent Developments
Table 154. Allergan Company Details
Table 155. Allergan Business Overview
Table 156. Allergan Influenza (Flu) Antiviral Drugs Product and Services
Table 157. Allergan Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 158. Allergan Recent Developments
Table 159. Takeda Company Details
Table 160. Takeda Business Overview
Table 161. Takeda Influenza (Flu) Antiviral Drugs Product and Services
Table 162. Takeda Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 163. Takeda Recent Developments
Table 164. Boehringer Ingelheim Company Details
Table 165. Boehringer Ingelheim Business Overview
Table 166. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product and Services
Table 167. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Revenue in Influenza (Flu) Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 168. Boehringer Ingelheim Recent Developments
Table 169. Influenza (Flu) Antiviral Drugs Market Trends
Table 170. Influenza (Flu) Antiviral Drugs Market Drivers
Table 171. Influenza (Flu) Antiviral Drugs Market Challenges
Table 172. Influenza (Flu) Antiviral Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type: 2021 VS 2028
Figure 2. Penetration and Dehulling Inhibitors Features
Figure 3. DNA Polymerase Inhibitors Features
Figure 4. Reverse Transcriptase Inhibitors Features
Figure 5. Protein Inhibitors Features
Figure 6. Neuraminidase Inhibitors Features
Figure 7. Broad-spectrum Antiviral Drugs Features
Figure 8. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application: 2021 VS 2028
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Household Case Studies
Figure 12. Others Case Studies
Figure 13. Influenza (Flu) Antiviral Drugs Report Years Considered
Figure 14. Global Influenza (Flu) Antiviral Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Influenza (Flu) Antiviral Drugs Market Size 2017-2028 (US$ Million)
Figure 16. Global Influenza (Flu) Antiviral Drugs Market Size Market Share by Region: 2021 VS 2028
Figure 17. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region in 2017 VS 2022
Figure 18. Global Top 10 Influenza (Flu) Antiviral Drugs Countries Ranking by Market Size (US$ Million) in 2021
Figure 19. Global Influenza (Flu) Antiviral Drugs Market Share by Players in 2021
Figure 20. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Influenza (Flu) Antiviral Drugs Revenue in 2021
Figure 22. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Company in 2021
Figure 23. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 24. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 25. North America Influenza (Flu) Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 26. U.S. Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 27. Canada Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 28. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Company in 2021
Figure 29. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 30. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 31. Europe Influenza (Flu) Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 32. Germany Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 33. France Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 34. U.K. Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 35. Italy Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 36. Russia Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 37. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Company in 2021
Figure 38. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 39. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 40. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Share by Region (2017-2028)
Figure 41. China Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Japan Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. South Korea Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 44. India Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 45. Australia Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 46. Taiwan Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. Indonesia Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. Thailand Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. Malaysia Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. Philippines Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Vietnam Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Latin America Influenza (Flu) Antiviral Drugs Revenue Market Share by Company in 2021
Figure 53. Latin America Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2017-2028)
Figure 54. Latin America Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2017-2028)
Figure 55. Latin America Influenza (Flu) Antiviral Drugs Revenue Share by Country (2017-2028)
Figure 56. Mexico Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)
Figure 57. Brazil Influenza (Flu) Antiviral Drugs Revenue (2017-2028) & (US$ Million)

Write comment about above report:

Published By: QYResearch Group

Product Code: QYResearch Group2092505

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Influenza (Flu) Antiviral Drugs Market Research Report 2023 Antiviral drugs are a class of drugs for the specific treatment of viral infections. Highlights The global Influenza (Flu) Antiviral Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witness...
Global Influenza (Flu) Antiviral Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028 The Influenza (Flu) Antiviral Drugs market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growt...
Global Influenza (Flu) Antiviral Drugs Market Insights, Forecast to 2028 Influenza (Flu) Antiviral Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Influenza (Flu) Antiviral Drugs market will be able to gain the upper hand as th...
Global Influenza (Flu) Antiviral Drugs Market Growth (Status and Outlook) 2022-2028 As the global economy mends, the 2021 growth of Influenza (Flu) Antiviral Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Influenza (Flu) Antiviral Drugs market size is USD million in ...
Global and United States Influenza (Flu) Antiviral Drugs Market Report & Forecast 2022-2028 Influenza (Flu) Antiviral Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Influenza (Flu) Antiviral Drugs market will be able to gain the upper hand as th...
Global Influenza (Flu) Antiviral Drugs Market Research Report 2022 Influenza (Flu) Antiviral Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Influenza (Flu) Antiviral Drugs market will be able to gain the upper hand as th...
Global Influenza (Flu) Antiviral Drugs Market Research Report 2022 - Market Size, Current Insights and Development Trends The report focuses on the Influenza (Flu) Antiviral Drugs market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provi...
Global Influenza (Flu) Antiviral Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028 The Influenza (Flu) Antiviral Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and glob...
Global Influenza (Flu) Antiviral Drugs Market Size, Status and Forecast 2021-2027 Antiviral drugs are a class of drugs for the specific treatment of viral infections. Market Analysis and Insights: Global Influenza (Flu) Antiviral Drugs Market The global Influenza (Flu) Antiviral Drugs market size is projected...
(Post-pandemic Era) - Global The Influenza (Flu) Antiviral Drugs Market Segment Research Report 2021 Summary The global economy is expected to expand 5.6% in 2021,global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach gl...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *